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SUMMARY
Background: Inactivation of tumor suppressor genes plays an important role in
leukemia. The inhibitor of DNA methylation, 5-aza-2’-deoxycytidine (5AZA), can
re-activate these genes and is under clinical investigation for therapy of
leukemia. However, the optimal dose/schedule is flot known yet. The objective
of this study was to determine the minimal concentrations of 5AZA that will re
activate target suent genes in human myeloid leukemic celI lines and correlate
with drug cytotoxicity.
Materials and Methods: The effect of concentrations of 1 to 100 ng/ml of 5AZA
on the re-activation of p15 and p73 in KG1a myeloid leukemic cells and E
cadherin in HL-60 myeloid leukemic cells was evaluated by RT-PCR. The
amount of amplified DNA was quantified with an Agilent 2100 Bioanalyzer using
18S ribosomal RNA as reference standard. The mean values were compared
using ANOVA. The effect of 5AZA on inhibition of growth, DNA synthesis and
colony formation on these celI unes was also investigated.
Resuits: The extent of activation of the target genes was dependent on the
concentration of 5AZA. For p15, activation was observed at 5 ng/ml or greater
and for p73 and E-cadherin at 100 ng/ml of 5AZA. At these concentrations we
also observed inhibition of growth, DNA synthesis, and clonogenicity. Gene
activation and in vitro antileukemic activity increased with the concentration of
5AZA.
Conclusions: The in vitro antineoplastic and gene re-activation activity of 5AZA
is dependent on the concentration of this analog and appeared at low
concentrations in the range of 10 ng/ml.
Discussion: Translation from cellular models into clinical trials is complex.
Demethylation of any specific gene has not yet been validated as a surrogate
marker for cure. Based on our pre-clinical investigation, however, clinical trials
should target a minimal plasma concentration of 5AZA in patients with leukemia
inthe range of 10 ng/ml.
Key Words: 5-aza-2’-deoxycytidine, myeloblastic leukemia, methylation,
p15CDKN2B, E-cadherin, p73.
VRESUMÉ
Introduction: L’inactivation de gènes suppresseurs de tumeurs joue un rôle
clef dans la pathogénie de la leucémie. Le 5-aza-2’-deoxycytidine (5AZA), un
inhibiteur de la méthylation de l’ADN peut réactiver ces gènes et est
actuellement évalué dans le traitement des leucémies. Cependant le protocole
d’administration optimal n’est pas encore connu. L’objectif de cette étude est de
déterminer la concentration minimale de 5AZA capable de réactiver certains
gènes inactivés par la méthylation dans des lignées cellulaires myéloides
humaines et de corréler cette concentration avec la cytotoxicité du 5AZA.
Matériel et Méthodes: L’effet de différentes concentrations de 1 à 100 ng/ml
de 5AZA sur la ré-activation des gènes p15 et p73 dans la lignée
myéloblastique KG1a et de l’E-cadherine dans la lignée myéloblastique HL-60 a
été évaluée par RT-PCR. La quantité de l’ADN amplifiée a été quantifiée par
l’Agilent 2100 Bioanalyzer en utilisant l’ARN 18S ribosomal comme référence
interne. La moyenne des valeurs a été comparée par ANOVA. L’effet du 5AZA
sur l’inhibition de la croissance, la synthèse d’ADN et la formation de colonies a
aussi été étudié.
Résultats: L’ampleur de l’activation de ces gènes a été proportionnelle aux
concentrations de 5AZA. Pour le gène p15, l’activation a été observée à partir
d’une concentration de 5 ng/ml. Pour les gènes p73 et l’E-cadherine il a fallu
des concentrations de 5AZA supérieures à 100 ng/ml pour obtenir le même
effet. Déjà aux basses concentrations de 5AZA, on a observé une inhibition de
la croissance cellulaire, de la synthèse d’ADN et de la formation de colonies.
Conclusions: L’activité anti-néoplasique et la ré-activation génique du 5AZA
est dépendante de la concentration de cet agent et s’observe déjà à d’aussi
basses concentrations que de 10 ng/ml.
Discussion: La transposition en clinique de données obtenues in vitro est
complexe. On n’a pas encore démontré que la démethylation d’un gène
spécifique était corrélée avec la survie du patient. Cependant, en tenant
compte de nos résultats, une concentration de 5AZA à partir de 10 ng/ml
pourrait être recommandée pour les essais cliniques futurs de la leucémie.
Mots clés: 5-aza-2’-deoxycytidine, leucémie myéloblastique, méthylation,
p15CDKN2B, E-cadherine, p73.
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PART I: BACKGROUND
CHAPTER I: ACUTE MYELOBLASTIC LEUKEMIA
Acute Myeioblastic Leukemia (AML) encompasses a heterogeneous group of
diseases f rom a clinical, morphologic and a genetic point of view. However,
except for the promyelocytic variant, the same type ot treatment s employed for
ail. The standard treatment for AML is cytosine arabinoside (ARA-C) associated
with topoisomerase inhibitors and anthracylines/mitoxantrone. For acute
promyelocytic leukemia a similar regimen is used but ail trans-retinoic acid is
added.
in aduit patients younger than 65 years the survivai rate s oniy 40%1. j
chiidren this figure increases to more than 50%. The prognosis s better for the
promyeiocytic subgroup of ieukemia.
Cure in ieukemia s achieved with high morbidity due primariiy to the severe
toxicity produced by current chemotherapy. in some groups of patients the toxic
death rate is very high and iong-term effects are an unavoidabie burden.
The prognosis in patients with recurrent disease is poor. There is an urgent
need to test new drugs and regimens in order to improve the prognosis of this
disease and reduce the expected side effects of the treatment.
2CHAPTER II: EPIGENETICS
Epigenetics is defined as changes in gene expression that are caused by
mechanïsms that do not involve alterations in the DNA sequence23.
The major epigenetic changes are methylation of cytosine nucleotides, in the
promoter region of the gene and chromatin modifications such as acetylation of
lysine residues in core histone. These two epigenetic phenomena are closely
Iinked.
DNA methyltransferases are the main group of enzymes involved in
methylation. They transfer a methyl group to cytosine using S-adenosyl
methionine as a methyl donor. DNA methyltransferase 1 (DNMT1) plays a
tundamental role in methylation homeostasis (figure 2.1).
In mammalian cells 3% to 5% of the cytosine residues in genomic DNA are
present as 5-methylcytosine4. Approximately 70-80% of the methylcytosine
residues are found in CpG sequences4.
In 1980, Razin et al5 described the importance of DNA methylation as a key
element in gene function and differentiation. It also has a major role in
embryogenesis6.
DNA methylation induces silencing of gene expression by inhibition of
transcription. There are two main hypotheses which explain how DNA
methylation inhibits transcription’:
1. It has been proposed that transcription factors bind Iess weII to a
promoter that contains 5-methylcytosine. However, this event alone does not
explain the silencing of gene expression.
2. Other events are involved. Methylated CpG binding proteins MeCP1
and MeCP2, bind to the methylated promoter, which can also interfere with the
3binding cf transcription factors. A close link exists between DNA methylation
and histone deacetylation (figure 2.1), the two major epigenetic mechanisms,
which potentiate each other8.
The relation between acetylation and deacetylation is fundamental in gene
expression. Histones can be acetylated by histone acetyl-transferases and
deacetylated by histone deacetylases. DNA methyl-CpG binding domain
proteins and DNMT1 may recruit histone deacetylases to methylated promoters
which in turn deacetylate histones to maintain chromatin in the repressed state.
The silencing of tumor suppressor genes (TSGs) can play an important role in
cell cycle control resulting in unrestrained celI proliferation
— a major trait in the
definition of cancer.
Methylation cf specific TSG and an increase at the level of mRNA of the DNA
methyltransferases has been described in many tumors9.
4Figure 2.1: DNA methylation and histone deacetylation in the promoter region of
a candidate gene. A nucleosome s shown. A methylated CpG site allows the
binding of a 5-methylcytosine binding protein which recruits histone deacetylase
and changes the configuration of the histones to a compact form preventing
binding of the transcription machinery. Demethylation ot the CpG site f rees
MeCP2, transforming the histone structure into a loose form allowing
transcription.
NH3
DNA Demethylation DNA Methylation
H istone Acetyl ation H istone Deacetylation
CH2-C0
5CHAPTER III: METHYLATED GENES
3.1 Methylated Genes in Cancer
TSGs can be silenced either by mutation, deletion or methylation. Genes
involved in cancer invasion/metastasis suppression, DNA repair, angiogenesis,
and genes coding for tumor antigens have also been described to be silenced
by methylation in cancer9.
3.2 Methylated Genes in Acute Myeloblatic Leukemia
Several genes are reported to be methylated in AML: p16INK4A, p15CDKN2B
MDR1, MINT1, MINT 2, ER, WT1 and E-cadherin1012. The methylation status of
these genes can be used as markers to classify AML into different subgroups. It
is not known which methylated genes play the most important role in cancer.
p15 and p16 have analogous roles, p16 being more often deleted than
methylated.
Among the methylated genes in myeloblastic leukemia p15, p73 and E-cadherin
seem to be good candidate genes. They play roles in different celi pathways.
pi 5 gene (pi 5CDKN2B) is a gene located on chromosome 9p21. It encodes for
a protein that inhibits cyclin dependent kinase 4 and 6 complexes. These D type
cyclins, phosphorylate the retinoblastoma protein, which triggers the release of
transcription factors that are necessary to enter S phase13.
pi 5INK4B expression is usually inhibited by methylation. The tumor suppressor
gene pis is silenced by methylation in 61% to 100% of the myeloid leukemias14.
Patients with ALL or AML with p15 methylation may have a worse
prognosis14’15. Maloney described a possible role of the loss of function of p15
6in the relapse cf leukemia16. He reports that p15 became methylated in
leukemic ceils at recurrence, but flot ail authors confirmed this observation17.
The p73 TSG s related te p53 and plays a role in DNA repair and apoptosis. t
bas been reported to be methylated in primarily iymphoid ieukemia18’19.
E-Cadherin is an invasion suppressor gene. Since ieukemic bone marrow biasts
migrate in the blood stream, E-cadherin might piay an important role in the
physiopathoiogy cf this disease. in a study by Meiki et ai20, E-Cadherin was
observed to be methyiated in 78% cf ieukemic sampies from patients.
3.3 Methyiated Genes in Human Myeioid Leukemic Ceil Lines
There are some human ceii unes in which some genes are methylated and
siienced.
in KG1a myeloid leukemic ceii une, both p15 and p73 are completeiy
methylated and net expressed19223.
For HL-60 myeioid leukemic celi une, p73 is partiauiy methyiated whereas E
Cadherin s fuliy methyiated23’24.
7CHAPTER IV: CANDIDA TE GENES
p15, p73, and E-Cadherin are genes involved in leukemia and for which, we
have ceil unes where they are inhibited.
pi-s
p15 is in a region that is frequently mutated and deleted in a wide variety of
tumors. Its mRNA sequence is described on the GenBank accession number
NM_004936. p15 has a second isotype NM_078487 which contains an
additional internai region which leads to a translation trame shift when
compared to the first variant. It is located on 9p21. The gene is transcribed into
a mRNA sequence of 2378 bp. p15 has a high amount of GC.
E-Cadherin (CDH1)
The mRNA sequence of E-cadherin is described by GenBank accession
number NM_004360 and has 4828 base pairs. The E-cadherin gene is Iocated
on 1 6q22-1. It codes for an adhesion molecule of the cadherin superfamily, a
calcium dependent ceil-celI adhesion glycoprotein comprised of f ive
extracellular cadherin repeats, a transmembrane region and a highly conserved
cytoplasmic taU. Mutations in this gene are associated with gastric, breast,
colorectal, thyroid, prostate and ovarian cancer25’26.
p73 Tumor Suppressor Gene
The mRNA sequence of p73 TSG s described by GenBank accession number
NM_005427 and has 2234 bp. The p73 gene is located on 1p36.3. It s
expressed both as multiple alternatively spliced C-terminal isoforms, and as N
terminally deleted, dominant-negative proteins that show reciprocal functional
regulation.
8CHAPTER V: 5-AZA-2’-DEOXYCYTINE
5-Aza-2’-deoxycytidine (5AZA) (Decitabine®, Dacogen®) is a chem cal
analogue of pyrimidine nucleotide 2’-deoxycytidine, the carbon of position 5
being replaced by a nitrogen group. Its chemical structure s shown on figure
5.1.
It was first synthesized in 1964 by Plimi and Sorm and demonstrated in 1969 to
be a promising drug because of its antileukemic activity in animal models by
Veshy and Sorn.
92’-deoxycytidine
NH NHa
5-aza-2’- deoxycytidine
Figure 5.1: The bîochemical structure of 2’-deoxycytidine and its analogue
5-aza-2’- deoxycytidine
OH H
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5.1 Mechanism cf Action and Metabolism
5AZA is an analogue of deoxycytidine. Like the antileukemic drug, ARA-C, it is
an antimetabolite with good cytotoxic activity. ARA-C is a potent inhibitor of
DNA replication. The mechanism of 5AZA is different and related to its specific
hypomethylation action which can reverse the silencing mechanism ot
methylation27. Figure 5.2 demonstrates its demethylating effect.
5AZA enters the celi, like the other nucleosides, both by an active transport
system and by passive diffusion.
To be active, it has te be transformed into a triphosphorylated nucleotide by
deoxycytidine kinase and other kinases9. It s incorporated into DNA by a
reaction catalyzed by the DNA polymerase.
5AZA is metabolized by deoxycytidine-5-monophosphate deaminase and
cytidine deaminase to pharmacologically inactive metabolites.
The antitumor activity of 5AZA is complex to evaluate because of the delayed
antineoplastic action of the demethylating effect which induces terminal
differentiation9.
11
CM3 CM3
I CpGpG Tumor Supressor gene f Inactive gene
5ÀZÀ
f CpG CpG Tumor Supressor gene +
Fig 5.2: Demethylation of the CpG islands in the promoter region cf the TSG by
5AZA. The demethylation of the CpG islands of the promoter region (shadowed)
reactivates the target gene allowing the transcription into mRNA.
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5.2 5AZA in Cellular Models
5AZA induces differentiation in mammalian ceIls27, including myeloid leukemic
cel I s28’29.
In vitro it was more cytotoxic than ARA-C at the same concentrations30.
For human leukemic ceil unes, the minimal active concentrations of 5AZA were
demonstrated by Momparler et al31 to be in the range of 0.1iiM (23 ng/ml) for
48h exposure.
In the human lung squamous carcinoma celI une SK-MES 132, 5AZA at a
concentration of 100 ng/ml produced a loss of clonogenicity of 47.3% and 70%
for an 8 and 24 h exposure respectively.
Cameron et al33 demonstrated that concentrations of 1 tM (228 ng/mI) showed
marked demethylating activity after 1-5 days. Concentrations of 0.lpM (23
ng/ml) showed littie effect on demethylation in the gastric celI carcinoma line
RKO.
5.3 5AZA in Animal Models
5AZA showed potent activity in L1210 mice Ieukemia34. A 15 h i.v. infusion of
5AZA at a total dose ranging from 0.5 mg/kg to 22 mg/kg produced a high
percentage of demethylation and an increase in the lite span of the mice of
greater than 150%. At higher doses, 5AZA showed curative potential of murine
leu kem ia35.
In mice35, the antileukemic action of this drug is superior to ARA-C. There
appears to be a good correlation between the extent of inhibition of DNA
methylation and the antileukemic activity of 5AZA34.
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Pharmacokinetic studies in rabbits showed that after injection of 5AZA in a dose
of 1 .25 mg/kg over 15 minutes, the mean plasma levels were 3 tg/ml and after
a dose of 2.5 mglkg they were 7 gImI. In dogs they were 3 tg/mI at a dose of 2
mg/kg and 10 ig/ml at 4 mglkg. 5AZA is quickly eliminated, with biphasic
kinetics. The drug crossed the blood brain barrier, obtaining cytotoxic
concentrations in the CNS of 50% ot those observed in the plasma, but with a
longer half life36.
5.4 In Vitro Studies on Leukemic Cells from Patients and Anecdotical Cases
Momparler et al37 investigated the effect of 5AZA on DNA methylation in the
leukemic cells of 2 children, one with acute lymphoblastic leukemia (ALL) the
other with chronic myeloid leukemia (CML) before and after treatment of 5AZA.
They perlormed the same experiment on lymphoid CEM and HL-60 myeloid
leukemic celi lines. The patient with ALL had recurrent disease and received a
24 h infusion of 5AZA (24 mg/kg) and the patient with chronic myeloid leukemia,
received a 40 h IV infusion of 40 mg/kg of 5AZA. The cells were incubated in a
medium containing 6-3H-deoxycytidine. They analyzed the 5-methylcytosine
ratio (5-methylcytosine/5 methylcytosine + cytosine) content by high
performance liquid chromatography (HPLC) before and after treatment with
5AZA. At the end of therapy there was a reduction in methylation of around
80%. Exposure of HL-60 and CEM cells to 1tM of 5AZA for 24 h produced an
81 and a 68 ¾ reduction in methylation, respectively.
Pinto et al28 showed in vitro differentiation of leukemic blasts from patients,
using concentrations of 5AZA of 1 tM added to the medium every 12 h for six
times. He had previously reported that the optimal dose to induce differentiation
in an erythroleukemia celI line was 1 jiM (228 ng/ml) and that repeated pulses
of 1 tM (228 ng/ml) up to 6 iM (1368 ng/ml) given every 6 hours produced
maximal celI ditterentiation.
Gattei et al38 studied the effect ot 5AZA in acute myeloid leukemia cells from
patients not eligible for aggressive chemotherapy and who were candidates to
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receive 5AZA. In suspension the concentration of 5AZA required to reduce
survival to 10% of the control ceiis was 30 tM (1.43-121.7) and to reduce to
50% was 9,1 cM (0.43 — 36.7)1. The same experiment was done with the ceils
on methylceliulose. With this solid medium Iower concentrations were required
to achieve reduction to 10% or 50% survival. They were 16 cM (0.9-81.1) and
4.8 cM (0.27-24.5) for the D10 and D50 respectively. There was no good
correlation between the resuits obtained in the soiid and iiquid mediums.
4.5 Clinical Studies
PHASE I AND PHASE 1/11 STUDIES IN CANCER
Several Phase I studies were pubiished with 5AZA. Ail the studies described,
even those which are flot designated as phase 11H provided data on the
therapeutic response.
The tirst study by Rivard39 pubiished in 1981, was perlormed in chiidren with
leukemia (15 ALL, 7 AML) and 3 chiidren with solid tumors (Wilms tumor,
osteosarcoma, pulmonary blastoma). The starting dose was 0.75 mglkg given
as a 12 h infusion. The dose was escaiated to 36-80 mg/kg as a 40-h infusion.
At doses of iess than 20 mg/kg, there was no observable toxicity. The dose
limiting toxicity (DLT) was myelosuppression and the maximum tolerated dose
(MTD) was 80 mg/kg. Other side effects observed were: alopecia, nausea,
vomiting and diarrhea. In this study the response was also seen at doses less
than 17 mg/kg but the antileukemic effect observed — reduction of leukemic
blasts, bone pain, size of infiltrated testis was of short duration. The effect was
longer at higher doses. Noteworthy was the clearing of cerebrospinal fluid and
clinical improvement in 2 patients with meningeal leukemia.
In the subsequent studies, the MTD varied according to the study design and
the DLT was consistently myelosuppression.
‘le to reduce survival to 10% the concentration was 6,800 ng/ml (326 — 27,747 ng!mI) and b
reduce to 50% the concentrations needed were 2,074 ng/mI (98-8,367 ng/ml)
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In 1996 van Groeningen et a14° published a phase I study with 21 adult patients
with soiid tumors. He administered 5AZA as a one-hour infusion separated by 7
h. Treatment was repeated every 3 to 6 weeks. He started with 25 mg/m2
divided in two doses and the next steps were 50, 75, 90, 120, 180, 225 and 300
mglm2 divided in 3 doses. 5AZA was cieared very quickly from the plasma with
tlI2Œ of 7 minutes and tl/213 of 35 minutes respectiveiy. The DLT was
myelosuppression, which increased markedly after 90 mglm2. There were also
increases in creatinine. There was a partial response in one patient with a local
recurrence of an undifferentiated carcinoma. Ail the other patients had short
iasting stabilization or progression of the disease. The recommended dose was
75 mg/m per infusion, with a totai of 3 infusions given every 5 weeks.
in 1997 Momparler et al32 published a phase i-li study of 5AZA in metastatic
Iung cancer. Fifteen patients entered the study and received a single 6-8 h iv
infusion of 200-660 mg/m2 repeated every 5-7 weeks. They showed some effect
of the drug in this clinical setting. They also reported nausea and vomiting in
approximately 80% of the cases, increased bronchial secretions in 20%,
infection in 20%, mucositis in 13%, asthenia in 33%, loss of appetite in 20%,
myalgia in 13% and in a smail number of patients diarrhea, hiccups and dysuria.
The causal reiationship between 5AZA and the rare effects is difficult to
establish. it is flot always easy to distinguish the effects of the disease and
those of the drug.
Another approach is to use iow dose treatment to reduce hematopoietic toxicity
and retaifl clinical efficacy. Preciinical studies show that demethylation occurs at
Iow doses. issa et ai41 published recently a phase 1/11 triai on 48 patients with
refractory disease: 1 with ALL, 35 with AML, 7 with myeiodyspiasic syndrome
(MDS) and 5 with CML. Two patients were treated twice; they had a stem ceil
transplantation and relapsed in-between episodes. Cohorts of 6 to 8 patients
were treated with 5 mg/m2 daiiy for 10 days (cumulative dose per cycle 50
mg/m2) with a stepwise increase of 5 mg/m2 to 20 mg/m2 (cumulative dose per
cycle 200 mg/m2). After this phase two cohorts of 3 patients each were treated
with 15 mg/m2 for 15 and 20 days respectiveiy (cumulative dose per cycle 225
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mg/m2 and 300 mg/m2). Finally, a phase Il trial was undertaken with 1 1 patients
who received 15 mg/m2 daily for 10 days to evaluate drug activity (cumulative
dose per cycle 150 mg/m2). The daily doses were infused over one hour. The
cycles were repeated every 6 weeks. Overall objective responses were noted in
16 out of the 50 episodes (32%). In 9 (18%) a OR was observed. Among the 37
patients with AML, 5 (14%) achieved a OR and 3 (8%) had an objective
response. In the Phase Il group a response was observed in 6 of 11 patients
(55%), 2 having a OR. The median time to response was 45 days (range 16 to
70 days). Eight of the 9 ORs occurred after 1 cycle. The drug was well tolerated.
Even with these lower doses, myelosuppression was the major side effect.
Grade Il nausea, vomiting, diarrhea, skin rashes, liver dysfunction and
creatinine elevation were also observed, as was grade 11111V hepatic toxicity. In
such a study, DLT and MTD are difficult to evaluate. There was no correlation
between p15 methylation at baseline or after therapy and response to 5AZA.
However, for the methylation studies, peripheral blood was used without
fractioning the blasts from the other cells, and the percentage ot methylation
was low. Furthermore the technique used to quantify methylation, OOBRA, is
flot very sensitive.
Aparicio et al42 recently reported a clinical trial of 5AZA administered by
continuous infusion for 72 h at the dose levels of 20, 30, 40 mg/m2/day in
patients with metastatic solid tumors. The primary endpoint of the trial was to
find a dose of 5AZA with acceptable side effects for clinical use. At 40 mg/m2
Grade 4 neutropenia was seen in 1 of the 6 evaluable patients with 30 mg/m2
and 2 of the 5 evaluable patients with 40 mglm2. This latter was considered
unacceptable and Aparicio recommended 30 mg/m2. The other toxic effects
observed were fever, nausea, vomiting, constipation, weakness, anemia and
thrombocytopenia.
The major toxic effect of the drug, myelosuppression, was used for Bone
Marrow transplantation (BMT) conditioning43 in patients with OML who relapsed
after allogeneic related BMT. 5AZA was used as conditioning regimen with
doses escalated in 3 steps from 100 to 150 mg/m2 every 12 h for 5 days
(cumulative dose 1,000 mg/m2 to 1,500 mg/m2). The regimen was well tolerated
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with a response, either OR or PR, in 8 of the 14 patients with no patient having
stage 11111V toxicity.
OTHER STUDIES IN CANCER
Several phase Il studies with 5AZA either aione or in combination with other
drugs have been pubiished. The drug administration schedules and the overali
responses seen in these studies are summarized in the table 1 .1.
Testicular Cancer
ClaveI44 used 5AZA in 14 patients with non-seminomatous testicular cancer. A
dose of 75 mg/m2/dose was administered as a one-hour infusion 3 times a day.
The schedule was repeated every 5 weeks. No activity was observed and the
dose had to be reduced in 3 patients due to myelosuppression.
Chronic Myeloid Leukemia
In CML there are two studies by Kantarjian et ai45: In 1997, they treated 37
patients (20 in the blastic and 17 in accelerated phase). They administered 100
mglm2 of 5AZA as a 6-hour perfusion every 12 h for 5 days (cumulative dose
1,000 mglm2). Because of prolonged myelosuppression, the dose scheduie was
subsequently reduced to 75 mg/m2 in one-hour perfusion every 12 h for 5 days
(cumulative dose 750 mglm2). The major toxicity was myelosuppression
resulting in febrile episodes in 68% of the patients. The median time to recovery
of granulocytes above 500/mm3 was 48 days. Nausea and vomiting (12% of the
patients), diarrhea (17%) and mucositis (7%) were aiso seen. Objective
responses were noted in 25% of the patients in blastic phase and 53% of the
patients in accelerated phase.
Recently Kantarjian et al46 also confirmed the data in a bigger group. They
administered cumulative doses of 1,000 mglm2 per cycle (subsequently
decreased to 500 mg/m2). 5AZA was given as a 100 mglm2 infusion twice a day
for 5 days given over 6 h. 0f 64 patients in CML blastic phase, 28% achieved
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an objective response, 6 a complete hematologicai response. Among the 51
patients in the accelerated phase, 55% achieved objective responses. A median
of 3 cycles was necessary to achieve the best response. The major side effect
was myelosuppression.
Myelodysplastic Syndrome
Wijermans et al47 using 5AZA at 45 mg/m2/day given as a 4 h infusion every 8 h
for 3 days every 6 weeks in 66 patients with myeiodyspiasia showed that 5AZA
was effective in haif of the patients, mainiy those with the worst prognosis.
Daskalakis et ai48 demonstrated in vivo, the demethylation effect of 5AZA. He
studied the p15 gene in high risk MDS patients treated with 5AZA, using
bisuifite treated DNA PCR and sequencing. Among these 23 patients, 15 had
hypermethylation of p15 gene and 9 of those had a decrease of methylation
associated with cli nical response.
Lubbert et al49 and Wijermans et al5° showed that low doses of 5AZA induced
remission in eideriy patients with MDS. Lubbert et al49 studied the effect of
5AZA on the cytogenetics of patients with MDS in bone marrow sampies f rom
previous trials. These samples were taken prior to and after 5AZA treatment. He
showed major cytogenetic responses in 19 out 61 patients with clonai
chromosomal abnormalities and a reduced risk of death in patients achieving a
major cytogenetic response. Their results suggested that 5AZA treatment in
MDS might be iinked to its ability to suppress the abnormal clone.
Acute Myeioblastic leukemia
Richei5’ treated 16 patients with reiapsed leukemia, with 5AZA. Eleven were in
their first relapse (10 AML, 1 ALL) and 5 unresponsive to high or intermediate
dose ARA-C (4 AML, 1 ALL). The f irst group of 11 patients received 5AZA 125-
250 mg/m2 as a 6-hour infusion twice daily for 6 days, followed by Amsacrine
125-250 mg/m2 as a one-hour infusion on days 6 and 7. The other group of 5
patients had 5AZA as monotherapy 250-500 mg/m2 twice daily for 3-6 days.
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The 11 patients who were in their first relapse cf acute leukemia after a
minimum cf 6 mcnths cf cemplete remissien had a geed respense te treatment.
Eight (73%) achieved a cemplete remissien and 2 a partial ene. The secend
greup did net respend te 5AZA alene. The majer side effect described was
myeletexicity. Less frequent events included nen-bacterial peritenitis and
neurelegical cemplicatiens like hemiparesis er semnelence. These appeared
with higher desages and were censidered reversible.
Schwartsmann et al52 used the cembinatien cf 5AZA and daunerubicin fer the
inductien therapy cf AML in aduits. As f irst Une therapy, they treated S patients
with 4-heur infusien cf 5AZA 90 mg/m2, as f irst une treatment, daily days 1 te 5,
asseciated with daunerubicin 50 mg/m2 IV belus, daily en days 1 te 3. One te 2
ceurses with a 5 te 6 week interval were administered. 6 patients achieved a
cemplete remissien after 1 (5 cases) er 2 cycles (1 case).
Petti et al53 used 5AZA, 90-120 mglmg2 as a single agent given as a 4 h
infusien in 12 patients with peer pregnesis AML: 10 were fully evaluable, 3
achieved a OR and ene a PR. Except fer myelesuppressien the texicity was
mild.
Gattei et al38 treated 9 patients with AML, net eligible fer standard treatment,
with 5AZA 90-120 mg/m2 as a 4 h infusien ebtaining 2 OR and 2 PR.
Willemze et al54 treated 63 adult patients with relapsed AML with 5AZA 125
mg/m2 as a 6-heur infusien every 12 h fer 6 days in cembinatien with either
amsacrine 120 mg/m2 as ene-heur infusien en days 6 and 7 (n=30) er idarubicin
12 mg/m2 as a 15 min infusien en days 5 te 7 (n=33). Twenty-three patients
(36.5%) ebtained a cemplete remissien after 1 er 2 cycles. Majer grade III and
IV gastreintestinal, cardiac, neurelegical and infectieus texicity was ebserved in
a higher percentage cf patients than what was seen with a classical inductien in
histerical studies.
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STUDIES IN SICKLE CELL DISEASE
5AZA has also been used in sickie celi disease to demethylate the y-globulin
gene inhibited by methylation.
A Phase I study55 determined the effect of repeated 5AZA dosing on
Hemoglobin F (HbF) levels and hematologic toxicity over a 9-month treatment
period. Seven patients were entered. 5AZA was administered by intravenous
infusion at a starting dose of 0.3 mg/kg per day, 5 days a week for 2 weeks,
followed by a 4-week observation period. Average HbF and average maximal
HbF levels attained during the last 20 weeks of treatment for the 6 SS patients
increased to 13,93% +1- 2.75% and 18.35% ÷1- 4.46%, respectively, f rom a
pretreatment mean of 3.12% +I 2.75%. Mean and maximal hemoglobin levels
increased from 7.23 +1- 2.35 g/dl to 8.81 +1- 0.42 g/dI and 9.73 +1- 0.53 g/dl,
respectively.
Koshy et al56 treated 8 adults with sickle cell diseases, 5 of whom were treated
previously with hydroxyurea, with doses ranging f rom 0,15 mg/kg to 0,30 mg/kg
given 5 days a week for 2 weeks. 5AZA was injected IV as a 4 to 7 minute
perfusion. They observed, in this pilot study, an increase in HbF including an
increase in patients previously treated with hydroxyurea.
Saunthararajah et al57 used 5AZA 0.2 mg/kg 1 to 3 times per week in 2 cycles
of 6 weeks duration with a 2 week interval between cycles, If there was a
response, the dose was reduced in the next cycle. He used this scheme in 8
patients resistant or intolerant to standard treatment with hydroxyurea. The
treatment increased the HbF and decreased the features of viscosity.
5.5 Dose Schemes Used in Phase II Clinical Studies in Cancer
The different schedules of 5AZA used in phase II clinical trials in patients with
cancer are shown in table 5.1.
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Pathology Dose scheme Perfusion Cumulative Nber 0f Nber 0f Objective Response Reference
time dose per cycles patients (OR)
(hours) cycle (mg/m2)
Relapsed 250-500 mg/m 6 1,500
— 1 16 (11 in the Associated with amsacrine Richel et al
AML bd (isolated) for 6,000 first relapse) 8 CR of the 11 in the first 1991e’.
3 te 6 days relapse
125-250 mg/m2 2 PR in the 5 others
(amsacrine) 6
days
Testicular 75 mg/m2tid 1 225 q5 weeks 14 None Clavel et al
cancer
AML 90-120 mg/m2 tid 4 810-1080 q4 to 6 12 3 CR, 1 PR Petti et al 1993
for 3 days weeks (10 evaluable)
AML 90-120 mg/m2 tid 4 810-1,080 Several 4- 9 4 OR, 2CR Gattei et al
for 3 days 6 weeks 1 993
MDS 50 mg/m2/day, 72 150 Maximum 29 54% OR Wijermans et al
3days 8 q6 CRin27% 1997°
65 mg/m2/day, 195 weeks
3 days
AML 90 mg/m 4 5-6 weeks 1 to 2 8 (6 Associated with daunorubicin Schwartsmann
od, day 1 to 5 evaluable) CR in 6 patients et al 1 99752
CML 75-100 mg/m2 6 750-1,000 Several. 37 Blastic phase OR 25%, CR 10% Kantarjian et al
q12 h for 5 days Clinically 20 in blastic Accelerated phase OR 53% J 997
indicated phase
17 in
accelerated
phase
Relapsed 125 mg/m2 q12 h 6 1,500 ‘2 63 CR in 36,5% after one or 2 Willemzee et al
AML or ALL for 6 days courses associated with either 99754
amsacrine or idarubicine.
MDS 45 mg/m2/day in 4 135 q6 weeks 66 OR 49% (OR 64% in patients Wijermans et al
3 div ided doses with a high risk core) 2000
x3
CML 75-100 mg/m2 6 750-1,000 several 130 Blastic phase 28% OR, 6 CR Kantarjian et al
q12 h for 5 days 64 in blastic Accelerated phase 55% OR 2003*46
phase 42% CR
51 in
accelerated
phase
* subsequently reduced to 750 mg/m recommends 500mg/m2 e 50 mg/m2 in q 12 hours for 5 daysJ
Table 5.1: Different dose schedules of 5AZA used in phase Il clinical trials in
cancer and the objective responses.
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5.6 Clinical Pharmacokinetics and Pharmacodynamics
In a phase I study Rivard et al39 used a bioassay based on growth inhibition of
[1210 leukemic celis in ceil culture. The steady state at the end of 24-40 h
infusion was 500 ng/ml (2.1 pM) (range 300-900 ng/ml) (1.3-3.9 pM) when the
infusion was normalized to 1 mg/kglh.
Richel et al51 with doses of 21 mg/m2/h given as a 6 hour infusion twice daily
had mean plasma concentrations of 0.6-1.2 pM (137-274 ng/mI). At dose rates
of 42 mg/m2/h and 84 mg/m2/h the plasma levels were 2 pM (456 ng/ml) and 5
pM (1,l4Ong/mI) respectively. After discontinuation the plasma half-life was 8-
14 minutes.
In a phase I study with solid tumors, van Groeningen et a14° for the doses of 75
to 100 mg/m2 obtained the peak plasma concentration of 207 ng/ml (0.93 pM)
and 458 ng/mI (2.01 pM) respectively. In one case of 30 mg/m2 and another of
60 mg/m2 the peak plasma concentrations were determined to be 56 ng /ml
(0.244 pM) and 93 ng/mI (0.409 pM). He used a bioassay based on growth
inhibition in L1210 leukemic ceils in mice.
Aparicio et ai42, studied a group of 16 adult patients with metastatic solid
tumors. In two patients receiving 5AZA at 30 mg/m2 over 72 h the plasma levels
were 0,12 (27 ng/mI) and 0.16 pM (36 ng/ml). These are the lowest reported
values associated with a biological effect: in vitro demethylation.
Momparler et al32 in a phase 1/11 study in lung cancer examined the levels of 7
patients by HPLC. The steady state levels of the 100 mg/m2 in 6 h were 390
ng/ml by HPLC and by bioassay, 310 ng/mI. Forthe 660 mg/m2in 8h perfusion
the mean concentration was 900 ng/ml (3.9 M) by HPLC and 640 ng/mI (2.8
pM) by bioassay.
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In OSE the concentrations of 5AZA were 20% of those in the plasma in patients
with ieukemia58
In a review, Momparler59 mentioned that the effective cytotoxic concentration of
5AZA is probably around 1 pM (220 nglml). In vivo the optimal plasma
concentrations for 5AZA are probabIy in the range of 0.1 - 1 jiM, the range of Km
of 5AZA59. Since the haif-life of 5AZA is short 15-20 min37 and the average ceil
cycle in AML is 60 h31 with a range up to 90 h, Momparler suggested that the
drug should be administered as a 90 h infusion.
Except for the resuits published by Aparicio42, ail 5AZA data was obtained using
the endpoint cytotoxicity or differentiation, but not demethylation. Very few data
exist about the necessary concentrations that demethylate the candidate genes.
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PART II: OBJECTIVE 0F THE STUDY
CHAPTER VI: OBJECTIVE 0F THE STUDY
The main objective ot this study was to investigate the minimum concentration
of 5AZA that would produce activation of p15, p73 and E-Cadherin in human
myeloid leukemic celi mes KG1a and HL-60.
A secondary objective was to investigate the effect of 5AZA on growth, DNA
synthesis and clonogenicity with the same experimental conditions used to
study gene expression and to correlate antineoplasic activity with gene
expression.
Our hypothesis is that there is correlation between the concentrations required
to re-activate gene expression and produce a significant antileukemic effect.
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PART III. EXPERIMENTAL
CHAPTER VII: MA TERIAL
5-aza-deoxycytidine (5AZA)
5AZA was obtained from Pharmachemie (Haarlem, The Netherlands) as a
sterile powder. It was dissolved in phosphate buffered saline PH 7,4 and stored
at -7O C. t was diluted in 0,45% sodium chloride on the day of the infusion and
used immediately.
Ceil Lines
Human myeloid leukemic ceils HL-60 and KG1a were obtained from ATCC,
Manassas, Virginia, USA.
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CHAPTER VIII: CELL CULTURE AND IN VITRO TESTING 0F 5AZA
8.1 Rationale
The antineopiasic effect of 5AZA can be tested in vitro in different ways.
Clonogenic assays6° have the greatest potential to predict the effect of the drug
in vivo but are particularly time consuming. Other authors61 confirmed this
information. They showed in myeloblastic ceils that the ability to clone in vitro is
associated with a poor response to therapy in vivo. There are more rapid
assays that can predict drug sensitivity like growth inhibition and inhibition of
DNA synthesis62.
8.2 Methods
To illustrate the effect of the drug: growth inhibition, DNA synthesis inhibition
and clonogenic assays were pertormed under the same conditions. Oeils were
observed on microscopy regulariy to look for any infection and their general
aspect.
8.2.1 OeIl Culture
Both cells mes were cultured in RPMI 1640 medium (Invitrogen, Burlington,
Ontario, Canada) supplemented with 10% heat-inactivated fetal bovine serum
(Wisent, St-Bruno, Quebec, Canada). The cells were incubated at 37°C in a 5%
C02 atmosphere. AIl experiments were done when the cells were in good
condition: weeks after unthawing, with an intact appearance on microscopy and
having normal doubling times, ie 16-18 h for HL-60 and 27-30 h for KG1a.
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8.2.2 Growth Inhibition
For growth inhibition, as for clonogenic assays and inhibition of DNA synthesis,
the KG1a ceils were treated with 5-AZA at time 0. No further drug was added
and the medium wasn’t changed. HL-60 cells were treated at time 0, 24 hours
and 48 hours and the medium was changed. This was done according to
previous experience in the Iaboratory. The celis were counted at 72 hours in
both cases.
8.2.3 Clonogenic Assay
For HL-60 a clonogenic assay was pertormed by studying the ability of 5-AZA to
inhibit colony formation. The ceils were incubated with drug for 3 days then
centrifuged and suspended in drug f ree medium. An aliquot of 100 cells was
placed in 2 ml of 1.8% soft agar medium containing 20% serum. After 15 days
incubation at 372C in 5 ¾ C02 incubator the number of colonies (>500 cells)
was counted.
The clonogenic assay was not performed for KG1a cells since this celI une does
not form colonies in soft agar medium.
8.2.4 Inhibition of DNA Synthesis
The inhibition of DNA synthesis was measured by the incorporation of
radioactive thymidine into DNA. Both ceIl mes were cultured in 5 ml flasks and
treated at time O for KG1a and at time 0, 24 h and 72 h for HL-60. At 72 h the
supernatant was discarded and the ceils were diluted in 5 ml RPMI with 5%
dialyzed serum. 1.25 pCi of {3H] - Thymidine (ION, Irvin, CA, USA) was added
(5pI of 3H-TdR lmCi/l diluted 1 in 4 in phosphate buffered saline) followed by
C02 and the cells were incubated for 6 h. During that time the flasks were
shaken manually every 30 minutes. The cells were then put on a GFIC filter,
previously wet with 3 ml of 0,9% NaCI. The filter was washed with 3 ml of NaCI
0.9%. The cells were fixed with 3 ml cold 5% trichloroacetic acid. The filter was
28
washed with ethanol and dried during 10 min in an oven before being placed in
ECOLite scintillation liquid (ICN). The radioactivity was measured using a
Beckman LS 6000 10 scintillation counter.
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CHAPTER IX: DESIGN 0F PRIMERS
The primers are an essential part of the PCR. They anneal with each of the
DNA strands and are fundamental in starting the reaction. The primers were
designed to the candidate genes and house keeping genes.
9.1 House Keering Genes
The house keeping genes are constitutional genes expressed in ail the celis
and used as internai controls for the PCR. We used f3-2-microglobulin and 1 8S
ribosomal genes.
fa-2 Microglobulin mRNA is described on the GenBank accession number
NM004048 and has 925 bp. The t3-2 microglobulin gene is located on
chromosome 15. t codes for a 11 kDa protein associated with the outer
membrane of many ceils including lymphocytes. t s a small subunit of the
major histocompatibility complex class I molecule.
18S ribosomal mRNA is described on the GenBank accession number X03205.
and has 1869 bp. The 18S ribosomal gene is situated on chromosome 1. Its
protein is fundamental for the protein synthesis machinery. it is highiy
expressed in ail the cells and was used as our major internai standard. 3-2
microglobulin was used as an extra control.
9.2 deal Primers
To have a maximal effect the primers should be 20-25 nucleotides long and
have GC content of 40-60%. The higher the GC context the higher the
annealing temperature. The Tm should be between 55C and 65C. The primers
should not hybridize with each other to avoid primer dimmers. Preferentially the
primers shouldn’t have a T at the 3’ terminus. The sequence of the primers
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should be taken from different exons to avoid amplifications of genomic DNA
during RT-PCR.
The primers for RT-PCR were designed using the nucleoside database. The
RNA sequence was copied into the OLIGO program where it is analyzed and
the best sequence for the primers chosen.
For each gene several primers were chosen and checked with positive controls,
DNA existing in the Iab where the candidate gene was known to be positive.
9.3 Selected Primers
Amongst the several primers analyzed we retained the following ones:
For 32-microglobulin sense 5’ GAT GAG TAT GCC TGC CGT GTG A 3’,
antisense 5’ CAA ACC TCC ATG ATG CTG 0H ACA 3’ amplify a 94 bp
p roduct.
For YSS, sense 5’ TCG ATG GTA GTC GCC GTG OCT A 3’, antisense 5’ CTG
CTG CCT TCC TTG GAT GTG GTA 3’ amplify a 110 bp product.
For p15, sense 5’ 0GO AGA CCC TGC GAG TCT CA 3’, antisense 5’ AGG
CAT 0GO GCA GGT GGA 3’ amplify a 113 bp product.
For p73 two sets of primers were used. The first set were sense 5’ GCA CCA
GGT HG AGG AGG TGT GGA 3’, antisense 5’ GAA TOC GH 00G 0GO ACO
AC 3’ amplify a 106 bp product and the second set, sense 5’ GAG GCA OTG
GTG GA 3’, antisense 5’ AGG GAG GGG AGG HG TTC A 3’ amplify a 134 bp
product.
For E-Cadherin, sense 5’ CAC AGG AGT CAT GAG TGT GGT GAG 3’,
antisense 5’ GAG OH GAA GGT GAG GAG GTT G 3’, amplify a 92 bp product.
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9.4 PCR Amplifications
For each gene the conditions for RT-PCR amplification and the reaction
mixtures (25 iiI) were found by trial and error in order to determine the best
temperature conditions, the minimal number of cycles to give an amplification
and the best mixture. Ail the mixtures contained 2.5p.l of iX PCR buffer, 1 pi of
dNTP, 0.5 tl of each primer (2.5 pM) and 0.2 pi of Hot Start Taq polymerase
(Qiagen) 5 units/pi. For the mixture the following solutions were tried when the
primers didn’t show a good amplification:
Q solution: a solution designed to modify the melting behavior of DNA
DMSO has been known to improve the amplification of some GC-rich
DNA sequences, inciuding some resistant to amplification by standard
PCR techniques. It increases the amount of the product.
Mg2SO4 In addition to Mg ions bound by the template DNA, the
nucleotides (dNTPs) and the primers, Taq DNA polymerase also requires f ree
Mg ions. It influences primer annealing, the melting temperature of the PCR
product and product specificity. An excessively high concentration leads to a
reduction of specificity.
Solution Q was added in the reactions to p73 and p15.
The concentrations used were in accordance of Qiagen® recommendations.
When the attempts failed a new primer was designed.
The FOR amplifications were done under the following conditions: 9SC for 15
min (activation of the Taq polymerase) followed by:
- For 1SS: 94C for 45 s (denaturation), 6OC for 30 s (anneaiing), 72C
for 30 s (extending) for 5 cycles. Then the denaturation step was shortened by
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15 s and the annealing temperature lowered by 2 degrees for 15 cycles. The
PCR finishes with 10 min at 72C and 10 min at 102C.
- For p15: 94C for 45 s (denaturation), 6220 for 30 s (annealing), 722C
for 30 s (extending) for 5 cycles. Then the denaturation step was shortened by
15 s and the annealing temperature lowered by 12C for 35 cycles. The PCR
finishes with 10 min at 72C.
- For p 73 (f irst set of primers): 942C for 45 s (denaturation), 6220 for 30
s (annealing), 72C for 30 s (extending) for 5 cycles. Then the denaturation step
was shortened by 15 s and the annealing temperature lowered by 2C for 37
cycles. The POR finishes with 10 min at 7220 and 10 min at 1020.
- For p 73 (second set of primers): 9420 for 45 s (denaturation), 6220 for
30 s (annealing), 72C for 30 s (extending) for 5 cycles. Then the denaturation
step was shortened by 15 s and the annealing temperature lowered by 2C for
35 cycles. The PCR finishes with 10 min at 72C and 10 min at 1020.
- For E-Cadherin: 94C for 45 s (denaturation), 58C for 30 s (annealing),
72C for 30 s (extending) for 5 cycles. Then the denaturation step was
shortened by 34 s and the annealing temperature lowered by 2C for 15 cycles.
The PCR finishes with 10 min at 72C and 10 min at 10go.
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CHAPTER X: RT-PCR
10.1 Rationale
Reverse transcriptase PCR (RT-PCR) is an in vitro method for enzymaticaliy
amplifying defined sequences of RNA in the form of cDNA.
When RNA is extracted the amount of RNA is measured by spectrophotometry.
An equal amount of RNA is transformed by the reverse transcriptase in cDNA
on which a classical PCR can be done.
10.2 Methods
After ceil growth with different concentrations of 5AZA, total RNA was extracted,
cDNA was made and the house keeping genes and the candidate genes were
looked for.
10.2.1 RNA Extraction
The ceils were harvested at 72 h and the RNA extracted using Absolutely RNA
RT-PCR miniprep kit63 (Stratagene, San Diego, CA, USA). After 72 hours of
incubation with the drug, the celis were lysed using Lysis Buffer with 3-
mercapto-ethanol. Then the total RNA was extracted. Ail the material was
RNAse f ree and the filters were protected with guanidine thiocyanate which
destroys RNA5e. The celis were successively fiitered with 70% ethanol and
different buffers prepared specially by Stratagene® for this effect. Then the
homogenate was put on a fiber matrix and treated with DNAse. In this
experiment we used DNAse Roche 10 U/mI, 2d diluted in 5i 1 Dx DNAse buffer
and 43 tl RNAse free water. It was incubated at 37 for 30 min. Again the
homogenate was f iltered through some buffers. Finally the homogenate which
contained the RNA was placed in a fiber matrix and incubated with water which
dilutes the RNA.
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The amount of RNA in each sample is measured by a Beckman DU-600
photometer using the absorption for 3 light length X260, À280, À230, the 2 latter
to allow us to assess contamination.
10.2.2 cDNA
For cDNA synthesis63, 500 ng of total RNA was reversed transcribed using
OmniScript Rtkit (Qiagen, Missassaugua, Ontario). The reaction was performed
at 3l C during 1 h followed by 5 min at 93°C to inactivate the enzyme. The
mixture was prepared in 15 jil (7 d of RNAse f ree water, 2 tl of 10 x Buffer RT,
2 d of DNTPs 5 mM, 2 tl of hexanucleotide mix 10 x (Roche) 1 il of RNAse
inhibitor (10 U/ml) and 1 tl of Reverse Transcriptase 2U/d. The reaction was
performed with 20 pi — 15 pi of the mixture and 5 of a mixture of 5 pi RNA and
water calculated to have approximately 500 ng of RNA per pi. A negative
control was done with the same mixture but without Reverse Transcriptase.
7 0.2.3 PCR amplifications
The PCR amplifications were pertormed as described in chapter IX. The cDNA
was checked for housekeeping genes 3-2-microglobulin and the 18S ribosome,
then the PCR was performed for the candidate genes.
35
CHAPTER XI: SEMIQUANTITA TIVE MEA SUREMENT 0F GENES
An absolute quantification cf the gene is flot necessary when testing the
expression cf a gene after treatment with different concentration cf a specified
medication. In such studies the increase in gene expression s the studied
endpcint.
We can relate the amount cf DNA cf the studied gene te a housekeeping gene;
in this study, we used mainly the 1 8S ribosomal gene.
77.7. Ethidium Bromide Agarose Gel Electrophoresis
Ethidium bromide s a fluorescent dye that intercalates between bases cf
nucleic acids and allcws detection cf DNA fragments in gels.
After amplitying the cDNA, PCR for a housekeeping gene is pericrmed. A
known determined amount cf the PCR reaction is put on a gel. After migration a
phctograph taken with a fluorescent light will reveal the amplitude cf the
migration band, which indirectly expresses the amount cf DNA present. By trial
and error, we find the amount cf DNA product which will give the same band
intensity on the gel after amplification. Since it is a hcusekeeping gene whose
DNA s present in apprcximately equal amounts in aIl cells, we concluded that
we therefore have the DNA frcm the same number cf cells in each band. That
amount wilI be used for the PCR for the studied gene.
The limit cf detection for 1% agarose gel is 0.1 ng.
77.2 Capillan,i Electrophoresis and Detection cf Fluorescence.
Capillary electrcphcresis associated with fluorescent high performance liquid
chromatcgraphy can be used to measure genes. This methcd was develcped
into an automated approach using the Agilent 2100 Bicanalyzer tAgUent
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Technologies, Palo Alto, CA, USA)64. Chips determine the size and amount of
DNA with high precision. Its limit of detection is 0.02 ng.
The amount of DNA amplified was analyzed by the Agilent 2100 Bionalyzer65.
The amount of each sample was normalized to the DNA concentration obtained
for 18S ribosomal gene. For each concentration ot 5AZA the amount of cDNA
which produced, after a PCR reaction, the same quantity (±10%) of 18s
ribosomal gene was found. That amount of cDNA was used in a PCR reaction
for the different TSG. To test the accuracy of the method used, a reference
curve was generated repeating the measurement with the same PCR product 3
times and 3 times with different PCR products but with PCR done under exactly
the same conditions.
77.3. ReaI-Time PCR.
Real time PCR63’66 is a very precise method for detection and quantification of
DNA. It has the advantage of detecting very small amounts of DNA.
There are two major Real-Time PCR methods: the standard curve method and
the comparative cycle threshold method. In the standard curve method the
amount of gene in the sample is calculated by comparison of a standard curve
for the specific gene. The cycle threshold method detects the relative gene
expression with a mathematical extrapolated formula.
In the standard curve method, which we used in the laboratory, the principle is a
fluorescent dye like SYBR green which is added to the medium and the PCR
product goes in a Real-Time machine which detects in “real time” the
fluorescence of the dye associated with the DNA for each cycle, comparing it
with the standard curve for the gene. The quantity of the gene present can be
extrapolated.
Real-time PCR based on SYBR green fluorescence and the standard curve
method was used for p15 with a Smart Cycler machine. The standard curve
was done based on known amount of pi 5 measured in the Bioanalyzer.
37
CHAPTER XII: DIFFERENTIATION 0F THE CELLS
12.1 Rationale
The demethylation effect of 5AZA has a slow mechanism of action.
Differentiation could be assessed by microscopy or more accurately by
quantification of neutrophil markers like CD11a,b,c and CD1567. This
differentiation appears only weeks after treatment. Richel et aI51, in patients with
ALL and AML, studied the cluster of differentiation before treatment and after 7
days of therapy. The loss of CD34 and the gain of CD33 in 3 patients was
suggestive of differentiation.
12.2 Methods
We used microscopic morphology and immunocytochemistry to analyze the
ceils before treatment to assess the kind of celis we were treating and after 72
h. Samples of HL-60 and KG1a were taken of the first and the last days of
treatment and colored with Wright stain and peroxydase.
To examine the ceils on which we were working, we also imunophenotyped
them at the beginning with the following monoclonal antibodies: CD33, CD13,
CD1 5, CD1 1 a,b,c. CD34, CD7, CD1 9, CD2O and CD2.
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CHAPTER XIII: DATA ANAL YSIS
Ail the experiments were repeated at ieast 3 times separated by at least one
week.
For each of the genes, the mean for each dose is obtained and anaiyzed by
one-way anaiysis of variance. The analysis s positive if at ieast 2 means are
different. To identify the mean which s different we used the multiple
comparison method with the SIDAK t test correction which has tighter bounds
than the Bonferroni test. The analysis were done using the SPSS 12 software.
Given the fact that the relative values obtained with Bioanalyser are
standardized for the 1 8s ribosomal gene our main analysis was done on the
basis of these values. We also did the same analysis on the ratio pi 5/1 8s and
examining the increase of p15 and of this rate above the baseline.
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PART IV: RESULTS
CHAPTER XIV: MANUSCRIPT: ACTIVATION 0F EXPRESSION 0F P75,
P73 AND E-CADHERIN IN LEUKEMIC CELLS BY DIFFERENT
CONCENTRATIONS 0F 5AZA
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Activation of Expression of p15, p73 and E-Cadherin
in Leukemic Celis by Different Concentrations
of 5-Aza-2’-Deoxycytidine (Decitabine)
NUNO J. fARINHA’2, SEPIDEH SHAKER3, MARYSE LEMAIRE3,
LOUISE MOMPARLER3, MARK BERNSTEIN’ and RICHARD L. MOMPARLER”3
1Service d’hematotogie-oncotogie, Hôpital Sainte-Justine, Montréa4 Québec H3T 1C.5, Canada;
2Division Pediatric Hematotogy and Oncology, Hospitat de S. Joclo, Al Hernani Monteiro, 4200-319 Porto, Portugal;
3Departement de pharmacologie, Université de Montréal and Centre de recherche,
Hôpital Sainte-Justine, Mon tréa4 Québec H3T 1C5, Canada
Abstract. Background Inactivation of genes tÏzat suppress
izeoplasia by abemint DNA inethytation is a key event that occurs
dwing the devetopment of teukemia. The inhibitor of DNA
methylation, 5-aza-2’deorycytidine (SAZ4), which can re-activate
these genes, is under clinicat investigation for therapy of leukemia.
The objective of this study was to detennine the concentrations of
5AZA titat will re-activate taget suent genes in human leukemic
ceit lines. Matenals and Methods: RT-PCR was used to evatitate
the effect of concentrations of 1 to 100 ng/ml of SAZA on the re
activation ofp15 andp73 in KG1a myeloid leukemic celis and E
cadherin in HL-60 myeloid teukemic ceils. The effect of5AZA on
inhibition ofgrowth, DNA ynthesis and colonyfonnation in these
ceit unes was also investigated. Resuits: The estent of activation of
the taiget genes was dependent on the concentration of5AZA. For
plS pronounced activation was obsen’ed at 10 ng/ml or greater.
Forp73 and E-cadhenn signtflcant activation was obsen’ed at 100
ng/ml of5AZA. Maximal initibition ofgrowth, DNA synthesu and
colonyforntation occurred at 100 ng/mL Conclusion: The in vitro
antincoplastic and gene re-activation activity of SAZ4 is dependent
on tite concentration of this analog. These data inay be helpftd in
die design of the optimal dose-schedule of SA ZA for the clinical
therapy of leukemia.
The silencing of the expression of genes that suppress
neoplasia by an epigenetic event, such as aberrant DNA
methylation, can play an important role during the
development of malignant disease (1). The cyclin kinase
Coriespondence to: Dr. Richard L. Momparler, Centre de
Recherche, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine,
Montréal, Québec H3T 1C5, Canada. ax: (514) 345-4801,
Key Words: 5-aza-2’-deoxycytidine, Icukemia, methylation,
p15CDKN2B, E-cadhcrin, p73.
inhibitor gene, p15CKN2B, the p53 gene homologue, p73,
and the ceil adhesion gene, E-cadherin, have been reported
to be silenced by DNA methylation in leukemia (2-4). 5-
Aza-2’-deoxycytidine (5AZA), a potent inhibitor of DNA
methylation, can re-activate the expression of many genes
silenced by promoter hypermethylation (5). In phase I-II
studies 5AZA was shown to be an active agent for the
therapy of hematological malignancies (6-9). Several clinical
trials on 5AZA are currently underway in patients with
leukemia. Preclinical studies of this analog can provide data
that can be helpful in the design of optimal dose-schedules
of 5AZA for clinical trials (10).
Materials and Methods
Materiats. 5AZA (Dacogen, Decitabine) was obtained from
Pharmachemie (Haarlem, The Netherlands). Stocks were made in
phosphate-buffered saline pH 7.4 and stored at -70’ C. HL-60 and
KG1a human myeloid leukemic ceils were obtained from ATCC,
Manassas, Virginia, USA. Both ccli lines were cultured in RPMI 1640
medium (Invitrogen, Burlington, Ontario, Canada) supplemented
with 10% heat-inactivatcd fetal bovine serum (Wisent, St-Bruno,
Quebec, Canada). The celis were incubated at 37’C in a 5% C02
atmosphere.
Drug treatment and in vitro assays. for KGÏa, different concentrations
of 5AZA were added to the medium once at time 0. For HL-60
leukemic ceils 5AZA tvas added to the medium at time 0, 24 and 48h.
For the growth inhibition assay, celis were counted at 72h using a
model ZM Coulter counter. For clonogenic assay, an aliquot of 100
cdils of HL-60 was placed in 2 ml of 3% agar medium containing 20%
serum. After 15 days incubation at 37’C in 5% C02 the number of
colonies (>500 cells) was counted. The rate of DNA synthesis was
measured by the incorporation of radioactive thyrnidine into DNA. At
the end of drug treatment, the ceils were centriftiged and suspended in
2 ml of medium containing 5% dialyzed serum and 0.5 iCi [3HJ
thymidine (6.7 Ci/mmol, ICN, Irvin, CA, USA) and incubated at 37’C
for an additional 6h. The celis were placed on GF/C glass fiber filters
(2.4 cm diameter), washed with cold 0.9% NaCI, 5% cold
0250-7005/2004 $2.00+ .40 75
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Table I. Growth inhibition and loss of clonogenicity by dtfferent
concentiations f5AZA ou FIL-60 aiid KGIa ,uyetoid teukemic celts.
5AZA FIL-60 KG1a HL-60
concentration growth inhibition toss of clonogenicity
(nglml) (%) (%) (%)
1 3.5 ± 5.1* 27.8 ± 3.2 31.3 ± 1.1*
5 nU 56.5 ± 3.3 nd
10 22.3 ± 8.9 59.6 ± 3.7 60.8 ± 11.2
50 36±8.8 nd 100±0
100 41.9 ± 11.5 67.5 ± 3.0 100 ± O
Drug exposure 72 h. *mean ± SD; n = 3-7. nd, not determined.
trichloroacctic acid and ethanol. The filters containing the DNA were
then dried, placed in scintillation liquid and the radioactivity measured
using Beckman LS 60001C scintillation counter.
Isolation ofRNA and RT-PCR analysis. Aftcr drug treatment the cells
were harvested and total RNA and cDNA prepared as previously
described (11). PCR was performed using HotStar Taq DNA
polymcrase (Qiagcn, Mississauga, Ontario, Canada) and specific
primers. Thc primers for 18S ribosomal RNA (GenBank accession
no. X03205) were sense 5’- TCG ATG GTA GTC GCC GTG CCI
A- 3’, antisense 5’- C1’G CTG CCT 1CC TTG GAT GTG GTA- 3’
which amplify a 110 bp product. for p15 (GenBank accession no.
NM 4936) the primers were sense 5’- CGC AGA CCC TGC CAC
TCF CA- 3’, antisense 5’- AGG CAT CGC GCA CGT CCA- 3’ and
amplify a 113 bp product. For p73 (GenBank accession no. NM
_005427) the primers were sense 5’- GCA CCA CGT 11G AGC
ACC TCT GGA- 3’, antisense 5’- GAA 1CC GTT CCG CCC ACC
AC- 3’ and amplify a 106 bp product. For E-cadherin primers
(GenBank accession no. NM _004360) sense 5’-CAC AGG AGI
CAl CAG TGT GGT CAC- 3’, antisense 5’ -CAC CII GAA GGT
CAG CAG CTT G- 3’ amplify a 92 bp product.
The PCR amplifications were done under the following
conditions: 95’C for 15 min followed by: for 18S ribosomal RNA:
94’C for 45 sec, 60’C for 30 sec, 72’C for 30 sec for 5 cycles
followed by 15 cycles of 94’C for 30 sec, 58’C for 30sec, 72’C for 30
sec and a single cycle of 10 min at 72’C and 10 min at 10’C. The
same program was used for piS cxcept the initial annealing
temperature was 62’C followed by 35 cycles with annealing
temperature of 61’ C. A similar program was used for p73 except the
initial annealing temperature was 62’C followed by 35 cycles with
annealing temperature of6O’C. For each gene, the number of cycles
tvas termïnated during the exponential phase of DNA amplification.
The PCR products were electrophoresed on 2% agarose gel and
detected by ethidium bromide staining. For quantitative detection of
gene expression we used 185 ribosomal RNA as the internai
standard. The amount of cDNA to use as template for cadi gene was
determined so that it would amplify the identical amount of 185
ribosomal RNA (±20%) during exponential phase. We mcasured
the absolute concentration of amplified DNA by the Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). This
instrument determincs the size and amount of DNA using capillaiy
electrophoresis and detection by fluorescence with high preeision.
The relative amount of amplified DNA for each specific gene to the
amount of amplified 18S RNA DNA vas quantified for each samplc.
Table II. Inhibition of DNA synthesis by different concentrations of
5AZA on HL-60 and KGb rnyeloid teukemic celts.
5AZA HL-60 KGIa
concentration inhibition of DNA synthesis
(nglml) (%) (%)
1 5.5 ± 5.1* 25.6 ± 5.3
5 nd 43.8 ± 13.4
10 20.0 ± 13.5 51.7 ± 21.4
50 49.5 ± 7.8 nd
100 52.1 ± 23.2 74.2 ± 10.8
Drug exposure 72 h. *mean ± SD; n = 3. nd. not determined.
Statisticat anatysis. For each of the genes the mean value for each
dose level was obtained and analyzed for variance. To quantitate
the difference between mean values, we used the multiple
comparison method with the SIDAK correction.
Resuits
Antineoplastic effeci of SAZA. Tise effects of different
concentrations of 5AZA on the inhibition of growth in
KOla and HL-60 leukemic celis after 72-h exposure are
shown in Table 1. The effect of different concentrations of
5AZA on inhibition of colony formation was evaluated by
clonogenic assay as is also shown in Table I. For both
leukemic ceil unes the inhibition of growth and colony
formation increased with the concentration of 5AZA. At the
concentration of 50 ng/ml of 5AZA we demonstrated a loss
of clonogenicity of 100% for HL-60 cells. The effect of
different concentrations of 5AZA on the inhibition of DNA
synthesis in KOla and Hi-60 ceils is shown in Table Il. for
both leukemic celi lines the inhibition of DNA synthesis
increased with the concentration of 5AZA.
Effect of SAZA on gene expression. The effect of different
concentrations of 5AZA on p15 gene expression in KG1a
myeloid leukemic ceils is shown in Figure 1. The expression
of piS increased with the concentrations of 5AZA as shown
by agarose gel stained with ethidium bromide and
quantitation of amplified DNA by Bioanalyzer analysis. The
greatest expression of piS was observed with 100 ng/ml of
5AZA, but significant expression of p15 was also obtained
witli 5 nglml of 5AZA. DNA methylation of p15 lias been
reported previously for KG1a leukemic cells (12).
In our analysis of p73 expression in KG1a cells, we only
detected gene re-activation at 100 ng/ml of 5AZA (Figure 2).
Lower concentrations of this analog did flot re-activate the
gene. For E-cadherin expression in HL-60 leukemic ceils we
detected some base line expression without drug treatment
(Figure 3). Only at 100 ng!ml of 5AZA did we detect a large
increase in expression of E-cadherin (almost 9-fold).
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p15
-113 bp
18S RNA
-110 bp
figure 1. Effect ofd,fferent concentrations of5AZA on the activation of
piS expression in KGJa myetoid leuke,nic ceits. The ceits were treated with
the i,tdicated concentratio,ts of5AZA. Total RNA was isolated at 72h for
RT-PCR anatysis by cihidium broniide staining agarose gel (A). 18S
ribosornal RNA was used as tue reference standard. 1, water; 2, no
treatrnent; 3, 5AZA I ng/rnl; 4, SAZA 5 ng/ml; 5, SAZA 10 ng/ntl; 6,
5AZA 100 nglmt. fiie ainount ofpIS DNA amptified was also detemzined
by Agitent Bioanatyzer (B).
Discussion
The rc-activation of gencs that suppress neoplasia by the
potent inhibitor of DNA methylation, 5AZA, a cytosine
nucleoside analog, is a nove! mechanism of action.
Optimization of its administration will help realize its full
potential since the antineoplastic activity of 5AZA is very
dose-schedule-dependent due to its S-phase specificity and
short in vivo half-Iife (6). In addition, therapy with 5AZA
can produce severe hematopoietic toxicity, its major side
effect (13).
The objective of this study was to find the in vitro
concentrations that produce a potent antineoplastic effect on
human teukemic ceil lines and to correlate these data with the
concentrations required to re-activate genes that suppress
leukemogenesis. Using 5AZA in the range of 1 to 100 ng/ml,
we observed that both the inhibition of growth, DNA synthesis
and colony formation increased with the concentration of this
analog (Tables I and II). It is interesting to note that 100 ng/ml
cont 1 5 10 100
Conc of 5AZA (ng/mI)
figure 2. Effect of different concentrations of5AZA on the activation of
p73 expression in KG1a myeloid leukeniic cells. The ceils were treated with
the indicated concentrations ofSAZA. Total RNA was isotated at 72h for
RT-PCR analysis by ethidium bromide staining agarose gel (A). 18S
riboso,nal RNA was used as the reference standard. 1, water; 2, no
treatrnent; 3, 5AZA I ng/ml; 4, SAZA 5 ngfml; 5, 5AZA 10 ng/ml; 6,
5AZA 100 ng/ml. The a,nount ofp73 DNA amphfied was also detennined
by Agitent Bloanalyzer (B).
5AZA, which produced a 100% loss of clonogenicity for HL-60
leukemic ceils, also leads to the most pronounced reactivation
of the expression of p15, p73 and E-cadherin. (Figures 1-3).
This correlation suggests that one mechanism by which 5AZA
produces an irreversible toss of clonogenicity is retated to its
re-activation of genes that suppress leukemogenesis. We do
flot know which are the most important genes involved in this
process. It is possible that the re-activation of other genes that
were flot investigated in this study are also required to block
colony formation by leukemic celis.
In an attempt to translate these data into clinical
application, it is tempting to speculate that the minimal
plasma concentration of 5AZA should be in the range of 100
nglml. In clinical trials on patients with leukemia, remissions
were observed when 5AZA was infused at a rate of 30
mg!m2/h, which produced plasma levels in the range of 200
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Figure 3. Effecl of different concentrations of5AM on rhe activation of
E-cadherin expression in HL-60 ,nyeloid teukeinic celis. ‘The cells were
ireated with the indicaled concentrations of 5AZA. Total RNA was
isotated at 72 h for RT-PCR analysis by etitidium bromide staining
agarose gel (A). 18S ribosornal RNA ivas used as the reference standard.
1, water; 2, no treatrnent; 3, 5AZA I ng/ml; 4, 5AZA 5 ng/ml; 5 5AZ4 10
tigimI; 6, 5AZA 100 ng/inl. The a,nount of E-cadherin DNA ainptified
was aLto deterntined by Agitent Bioanatyzer (B). E-cad, E-cadherin.
to 400 ng/mi (6,13). Lower doses of 5AZA were used to treat
patients with myelodysplastic syndrome (9). In these patients
5AZA was infused at a rate of 1.67 mglm2/h (9), which by
pharmacokinetic calculations should have produced a plasma
level in the range of 10 ng/ml. This concentration of 5AZA
showed significant te-activation of piS in leukemic ceil unes,
although to a lesser extent than seen at 100 ng!ml (figure 1).
The low dose therapy.of myelodysplastic syndrome with
5AZA produced demethylation and protein expression of
p15 in some patients (14).
future investigations on the analysis of gene re-activation
by 5AZA in patients with leukemia and correlation with its
response should also provide data that will assist in the
design of the optimal dosc-schedule for this analog.
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CHAPTER XV: OTHER RESULTS
75.7. Accuracy 0f the Agilent Bloanalyser and of the Method
To test the method, the PCR for a known amount of p15 was repeated 3 times
on 4 different amounts of p15 molecules (10, i05, 1O, lo7molecules)to obtain
a standard curve (see figure 15.1 and figure 15.2). The r2 coefficient of the
relation between molecules of p15 and concentration after amplification is 0,96.
This regression analysis shows indirectly the accuracy of the method.
A similar experiment, where the PCR was done only once for each
concentration but where we repeated 3 times the Agitent Bioanalyzer
measurement, showed a r2 of 0.99.
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Figure 15.1: Electrophoresis of the p15 standard curve. PCR reaction for p15.
The PCR were performed with the same conditions as those used in the study
of this candidate gene but on a known amount of molecules of p15. A sample of
p15 of our experiment was used. By Bionalyzser we measured the
concentrations of p15 and we calculated the number of molecules which were
then further dlluted.
Cont b7 106 w5
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p75 Standard Curve
14
i2rEEE0958
10000 100000 1000000 10000000
Number 0f p15 molecules
Figure 15.2: P15 standard curve. From each 0f the 3 PCR reactions done the
concentration of p15 was measured by Bionalyzer and put on a logarithmic
curve. The results are mean value ± SD. A Iog trendiine is shown.
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75.2. Gene Re-expression
Gene expression is described in the manuscript.
15.2.1 p73 Gene expression
For p73 using different primers (identified as primer 2) we obtain some
expression of p73 atthe concentration of 10 ng/ml. That is shown in figure 15.3.
For ail the other genes no difference was observed when testing different
primers including when we used Ç3-2-microglobulin instead of 18S ribosomal
RNA.
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Fig 15.3 Effect of different concentrations of 5AZA on the activation of p73
expression in KG1a using a second set of primers. The ceils were treated with
the indicated concentrations of 5AZA: 1, water; 2, no treatment; 3, 5AZA I
ng/mI; 4, 5AZA 5 ng/mI; 5, 5AZA 10 ng/mI; 6, 5AZA 100 ng/mI. Total RNA was
isolated at 72h for RT-PCR analysis by ethidium bromide staining agarose gel
(B). 18S ribosomal RNA was used as the reference standard C. The amplified
gene was measured by Agilent Bioanalyzer (A).
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15.2.2 Different Ways of Presenting the Re-expression 0f p15
In the manuscript, are presented the absolute values obtained in ng/pI. These
values were obtained with approximately the same amount of 18S in each
sample allowing us to assume the same amount of cDNA.
The analyses of variance of the different doses of 5AZA on p15 gene
expression showed a global effect (pO.001). When we look at the absolute
values of p15, there s an increase in p15 expression beginning at the
concentration of 1 ng/ml and statistically significant between 1 and 10
(p0.004). Between 10 and 100 ng/ml, 5AZA it keeps on increasing but without
statistical significance. The tendency analysis showed a linear increase starting
at 1 ng/ml until 100 ng/mI.
If we subtract the baseline value f rom the other values, the same effect s seen
(figure 15.4A).
We could also present the ratio of p15 gene by the 1SS ribosomal gene value
(figure 15.4B) or subtract from this ratio the baseline value (figure 15.40). In
both cases, the global resuit aiways remains very significant (p<0.001) and the
major increase remains between 1 ng/ml and 10 ng/ml.
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Fig 15.4: Effect of different concentrations of 5AZA on the activation of p15
gene expression in KG1a celis. The data is presented subtracting the baseline
value from the other values (A), reporting the ratio of the p15 gene
concentration to the 18S ribosomal gene concentration (ratio pl5IlSS) (B) and
subtracting the baseline ratio to this ratio (15/1SS minus the baseline ratio).
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75.3 CeIl Morphology and Differentiation
15.3.1 Microscopy
HL-60 cells are shown in fig 15.5A and KG1a celis are shown in fig 15.5B, using
a Giemsa Wright stain. HL-60 celis are celis with high nucleocytoplasmic ratio.
The cytoplasm is basophilic. The nucleus has loose chromatin and some
nucleoli. They tend to aggregate and sometimes form a syncytium (figure
15.5A). The peroxydase stain is negative.
KG1a celis are large irregular celis with high nucleocytoplasmic ratio. Some are
multinucleated and have several nuclei (figure 15.5B). The peroxydase stain is
negative.
We observed at several time points, the leukemic celis following Giemsa Wright
staining: at the beginning of treatment and at 72 h. At 72 h we did flot observe
more differentiated ceils like myelocytes, metamyelocytes, bands or neutrophils
or signs of apoptosis. Nor have we observed other types of cells.
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H L-60 ceils
KGIa ceils
B
Fig 15.5 Giemsa Wright staining of KGIa (B) and HL-60 (A) ceNs at 40x
A
magnification.
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15.3.2 Immunophenotyping
During one experiment the celis were phenotyped with anti-sera which usually
mark AML: once at the beginning and once at 72 hours following the beginning
of treatment with anti-sera for CD13, CD 33, CD7, CD15, CD1 1
Before treatment:
KG1a celis were CD13, CD33, CD7, CD15 positive.
HL-60 ceils were CD13 and CD33, positive.
At 72 h:
KG1a ceils were CD33, CD7, CD15, CD13, CD11a positive.
CD11b negative.
HL-60 ceils are CD33, CD1 3 and CD1 la positive CD1 lb negative
75.4. ReaI-Time PCR
Real-Time PCR was attempted several time for p15. First a standard curve was
pertormed which is shown on figure 15.6. But when run with the p15 gene, we
obtained several primer dimers which did not allow interpretation. This problem
could not be overcome with any of the sets of the primers.
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y = -0.30 lx + 11,669, r-squared = t).994
Fig 15.6: The standard curve for p15 using Rea Time PCR. In this curve there
are only shown the resuits of one experiment. The standard curve was repeated
several times by other researchers in the Iaboratory.
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PART V: DISCUSSION
CHAPTER XVI: DISCUSSION
5AZA has a novel mechanism of action of reactivating suent TSGs by
demethylation. This action can Iead to Ioss of cionogenicity of leukemic cells
due to induction of terminal differentiation or senescence. 5AZA is an S phase
specific agent with a short in vivo haif-life due to rapid inactivation by cytidine
deaminase. Ail these parameters shouid be taken into consideration in the
design of the optimal dose-schedule of 5AZA for the curative therapy of
leu kem ia.
Gene Re-activation
In this study 5AZA was shown to re-activate the TSGs, p15, p73 and E-cadherin
in human myeIoid leukemic celI unes and produced a significant antileukemic
effect that confirmed our hypothesis. It was possible to detect reactivation of
p15 at a concentration of 5 ng/ml of 5AZA, whereas reactivation of p73 was only
at 10 ng/ml and of E-cadherin at 100 ng/ml of 5AZA. The reason for this
difference in sensitivity s unknown. It is possible that t may involve the binding
of different proteins to methylated CpGs in the promoter region.
The reactivation of p15 by 1 ng/ml of 5AZA was more difficuit to assess and
depends on the way we look at our data. If we look at the mean plots of the
results in terms of the absolute value of DNA (nglpl), there seems to be some
reactivation but if we determine a ratio between p15 and 18s the expression at
1 ng/ml disappears. No matter the way we look into our data the major increase
of gene reactivation of p15 occurs between 1 ng/ml and 10 ng/mI (p<0.01). The
increase between O or 1 and 100 ng/ml was positive in ail cases (p< 0.001) and
100 ng/ml produced significant reactivation of aIl the genes studied. Further
studies should be undertaken to see which way of presenting gene re
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expression data would be most precise, using the absolute value of DNA, the
value relative to 18S expression or subtracting the baseline value.
We found some baseline gene expression of p15 and E-Cadherin in a celI une
supposed to be completely silenced. Hypermethylation of the CpG islands is a
highly heterogeneous and variable event11’68’69 Nevertheless the amount of
expression is so small that it could be considered in the range of the
background signal of the instrument and not due to real expression.
In this study we assumed that p15, p73 and E-Cadherin were completely
silenced by methylation as reported by other authors212224. Techniques like
DNA sequencing, microsatellite analysis and Southern blotting are needed to
show that the gene sequence is normal. The silencing is due to an epigenetic
phenomenon which can be demonstrated by bisulfite-DNA sequencing and
methylation specific FOR. Sodium bisulfite deaminates cytosine to uracil,
whereas 5-methylcytosine is resistant to deamination70. Using methylation
specific primers, methylation can be identified by FOR. For p15 in KG1a, Dodge
et al22 used sodium bisulfite DNA sequencing. They also looked for gene
expression of p15 by RT-POR and Western blotting. They showed that there
was no deletion or mutation in the p15 gene and it was highly methylated, with
more than 80% of the OpG sites methylated. In normal bone marrow the p15
gene was unmethylated and expressed. Corn et ai23, investigated the p73 gene
in the KG1a celi une. Using Southern blot analysis, FOR in single strand
conformational polymorphism they didn’t observe any abnormality in the
sequence of the p73 gene. They also showed by Southern biotting and
methylation specific PCR (MSP) that the gene was methyiated. In another
study, Corn et aI24 studied the HL-60 celI me looking for alterations in the E
Cadherin gene and gene expression. Genomic bisulfite sequencing showed
normal alleles, and full methylation. RNA transcription and protein expression
were absent. Peripheral blood mononuclear cells, used as control, were almost
unmethyiated. Furthermore, in these 3 studies a re-expression of the different
genes was shown after treatment with 5AZA. In our Iaboratory using MSP, t
was confirmed that these genes were methylated (unpublished data).
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Translation of data on in vitro gene activation to the optimal plasma
concentration of 5AZA for therapy of leukemia should be done with caution. The
reactivation of one or more TSGs by 5AZA does not necessarily result in a loss
of cionogenicity, the primary objective of the chemotherapy. Data on clonogenic
assays and pharmacokinetic analysis are more suitable for translation to
plasma concentration of 5AZA.
Pharmacokinetics
Pharmacokinetic and pharmacodynamic parameters should be taken into
consideration for the design of the optimal dose-schedule of 5AZA. 5AZA has a
very short half live of 15-20 minutes. It is mainly eliminated by deamination.
Cytidine deaminase is present in high leveis in the liver and spleen71 and in
lesser amounts eisewhere in the body. Those two organs are particularly
important due to leukemic cell infiltration. To obtain therapeutic concentrations
in liver and spleen, a higher dose is required, or alternatively an inhibitor of
cytidine deaminase couid be given (see below). In leukemia, 5AZA may
penetrate less in packed marrow but crosses the blood-brain barrier well with
CSF/piasma ratios in the range of 0.25-0.5 in animal models36. In a phase 1/11
ciinicai trial in children, Rivard et al39 showed that leukemic cells in the CSF
could be cieared by high doses of 5AZA.
In order to be active, 5AZA must be phosphoryiated by deoxycytidine kinase,
the rate-liming enzyme of the metabolic cascade of 5AZA. The concentration of
5AZA at which this enzymatic reaction takes place at 50% of its maximum
velocity (Km) is in the range of 10 pM (2,280 ng/mI)59. The optimal plasma
concentration for 5AZA would probabiy be in the range of this limiting Km to
obtain close to maximal activation of this analog. However such a concentration
would carry unacceptable toxicity unless a short infusion of 5AZA is used.
A key point to consider is that the concentration of 5AZA in ail anatomic
compartments during therapy will be different. If the concentration in any
anatomic compartment is below the minimal cytotoxic level, it will act as a
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sanctuary for the leukemic celis. The choice cf the dose of 5AZA must take this
into consideration.
Ce!! kinetics Considera tiens
5AZA acts in S Phase cf the ceil cycle and therefore s schedule dependent. So
the maximal tolerated individual dose given as a bolus dose might flot be the
most important parameter72. Raza et al73 estimated that the AML celi cycle
length was around 60 h (range 18-211). OnIy 6 of the 54 patients he studied
had cycles longer that 90 h. More recently this group provided additicnal data74
in 128 patients with AML who had median cycle times cf 45 h (range 11.5 —
211) with a median S phase time was 12 h (range 3.1 —35). ldeally, the duration
cf infusion cf 5AZA should be long encugh to permit ail cf the clonogenic
leukemic cells te enter the S phase.
Clonegenic Assays
A clonogenic assay measures the potential cf leukemic cells te form colonies in
vitro. Since the goal cf the chemotherapy is te destroy the proliferative potential
cf leukemic cells, the concentrations cf 5AZA and duration cf treatment that
completely block colony formation are cf key importance. These data are
difficult te obtain with leukemic cells f rom patients due te the large variability in
their in vitro growth characteristics. Different human leukemic cell unes can be
used for this purpose.
in this study the concentration cf 5AZA for a 72 h exposure that produced about
50% loss in clonogenicity was in the range cf 10 ng/ml for HL-60 myeloid
leukemic cells. At 50 ng/ml, for 72 h, 5AZA produced a 100% loss cf
clonogenicity for this cell me.
In studies on patients the concentration cf 5AZA to obtain 50% ceil death (1G50)
cf leukemic ceils from non-resistant AML patients is quite high, around 1 pM
(228 ng/ml). In a study by Gattei et al on clonogenic cells from patients with
AML the lowest 1050 was 0.43 pM (98 ng/ml)38. This high lC50 will change if we
use intermittent dosing providing more prolonged exposure75.
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Prior Clinical Studies on 5AZA
5AZA is now in phase III trials for MDS where small doses are used: 45
mg/m2/day for 3 days every 6 weeks with an overali response rate of 49%47• In
this clinical setting Issa et al41 showed an objective response in more than half
of the patients with doses as small as 5 to 20 mg/m2 given as one-hour infusion,
5 days a week for 2 weeks.
In CML, 5AZA at 75-1 00 mg/m2 over a six-hour infusion every 12 h for 5 days
showed objective responses in half of patients in accelerated phase and in one
quarter of the patients with blastic phase46.
AML was one of the f irst pathologies in which 5AZA was studied. Rivard et al39
in a phase 1/11 trial entered 15 patients with AML showing a response in a
majority of them. They used doses up to 80 mg/Kg and showed that when using
5AZA at 1 mg/kg/h (approximately 30 mg/m2/h) the plasma levels at 24 h were
around 500 ng/ml (300-900).
Richel et al51 in 1991 treated 11 patients in the f irst relapse of AML with 5AZA at
125-250 mg/m2 twice daily as six-hour infusions associated with amsacrine
showing 8 OR51. He confirmed the cross resistance between ARA-C and 5AZA
previously described.
Petti et al53 and Gattei et al38 tested 5 AZA in AML using doses of 90-1 20 mg/m2
as a single agent administered as a four-hours infusion showing overali
responses in more than 1/3 of the patients. Except for myelosuppression the
toxicity was mild. Petti recommended 5AZA as a component of therapy for
patients with poor general condition or advanced age.
5AZA was used in relapsed AML associated with either amsacrine or idarubicin
in a study that also included ALL and CML54. 5AZA was given as a six-hour
infusion every 12 h for 6 days. 57 patients with relapsed AML entered the study.
Among those, 22 obtained a OR after 1 or 2 cycles. Only 20% of the patients
were in remission atter 1 year. Hematologic and gastrointestinal toxicity were
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the most frequently seen. As a first une treatment in AML associated with
daunorubicin 50 mg/m2 day on day 1 to 3, it induced a CR in the 6 evaluable
patients52. 5AZA was given as a four-hours intravenous infusion of 90 mg/m2
daily for 5 days. A maximum of two cycles was administered. Myelosuppression
and mucositis were the major toxicities observed.
In AML, 5AZA at intermediate/high dose, given as a four-six-hours infusion is
active. The studies in which it was combined with other drugs entered small
numbers of patients and are too heterogeneous to allow conclusions.
Nevertheless the resuits seem as good as those obtained with classical
reg i mens.
Integration of Data for Translation into Clinical Trials
The recommended dose depends on the endpoint: demethylation, cytotoxicity
or survival. Methylation of the TSGs seems to be important in the
physiopathology of cancer and so demethylation could be a step to the cure. To
date, it is not clear which genes need to be demethylated for the cure of a
patient. Most important for the patient is long-term survival with Iimited side
effects. Studies need to be designed to see if re-expression of a specific gene
might be used as a surrogate marker for cure in pathologies where epigenetics
show a major role, among others, myeloblastic leukemia. Further, we do flot
know the exact amount of demethylation needed to have a real effect in the
clinic. For certain authors1168, the density of methylation within the CpG island
is the paramount factor of silencing and not methylation of any specific site.
Cameron et al68 showed in vitro that methylation ot CpG 40% in each allele is
necessary for silencing the gene but this is controversial. Full demethylation of a
gene may not be required to have real clinical effects.
If we look for demethylation, the therapeutic plasma levels are less than those
previously recommended of 1 pM3. Aparicio et al42 used 5AZA 30 mg/m2 given
over 72 h and obtained plasma levels of 0.12 pM (27 ng/ml) and 0,16 pM (36
ng/ml). They observed demethylation but no objective clinical response in
patients with cancer.
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We did flot observe any morphological signs of differentiation or apoptosis but
we only followed the celis for 3 days. We did flot use any specific marker of
apoptosis like annexin or any marker of differentiation. This was flot the
objective of the study. We phenotyped the ceils before treatment and after 3
days. This was done to see on which celis we had had an effect and was flot
repeated. At 72 h there were neutrophil markers ifl both celi Unes. This requires
confirmation in other studies. It would be interesting to see if there is any
correlation between an early appearance of neutrophil markers and gene
expression.
Translation into the clinic is particularly difficult when we use ceIl unes.
Mimicking pharmacokinetics in vitro is difficuit and uncertain particularly given
interpatient variability. The human myeloid leukemia celi unes HL-60 and KG1a
do flot have the characteristics of differentiated human myeloid celis: different
morphology, different staining characteristics and a tendency to aggregate and
eventually form syncytia. Nevertheless, morphology is becoming Iess important
in the classification and definition of cancer, with an increasing role of
genetics76. The leukemia cells studied have been cultured in vitro for years and
might have acquired different characteristics. On the other hand, compared to
leukemic ceils from the patient, they are homogenous and well studied.
Studying cells f rom a patient might allow the selection of different clones and
contamination f rom other human cells. This taises the problem of a good model
which has to be homogenous and reproducible and representative of the
studied cancer. The techniques used might also lead us into wrong translation.
In this study two different primers used to study p73 gave slightly different
resuits with expression of the gene starting at two different concentrations.
Pharmacodiagnostics
Pharmacodiagnostics have an increasingly important role in the choice of the
drug and dosage. Clonogenic assays have been shown to be good surrogates
for in vivo effect. They are more specific than DNA synthesis assays which are
easily periormed, although a good relationship between in vitro drug resistance
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and a poor clinical response to therapy has been seen using incorporation of
thymidine77. Today, there is an increasing number of new agents coming to
market. In some clinical settings, such as perhaps, non-response to a standard
drug regimen these tests can be used to select the best second une drug. They
can be associated with others like gene re-expression or the study of certain
polymorphisms78 to try to get a model to predict a response. It is fundamental
to improve our models to allow a better correlation between the preclinical and
clinical situations79.
Future Studies
Resistance to drugs is a feared event. Therefore cancer is treated with
multidrug regimens in order to overcome resistance and to increase efficacy.
Usually, regimens have drugs with different mechanisms of action. For 5AZA
there s a clear potentiating effect of the histone deacetylase inhibitors80’81. They
should be tested in combination and studied in such a way as to ascertain if the
acetylation/methylation status correlates with survival.
Zebularine is an interesting medication to test in association with 5AZA, in
cellular and animal models. It inhibits cytidine deaminase82 and might increase
the levels of 5AZA in liver and spleen.
Some drugs used mainly in solid tumors have shown some synergy when used
with 5AZA such as cisplatin8384 and topotecan85. A phase Il study has been
completed with cisplatin and 5AZA, showing a moderate effect on the advanced
squamous celi carcinoma of the cervix83.
In leukemia, there is an interesting synergy described with retinoids and
inter[erons66 which might be used in myeloblastic leukemia, perhaps particularly
promyelocytic leukemia.
Growth factors have also been recommended, myelosuppression being the
major limiting toxicity mainly at high doses where it has major cytotoxic
effects31. We could also test growth tactors during treatment with 5AZA to
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recruit ceils into S phase and increase the activity of 5AZA87. This is
controversial and would need strong animal model support before being tested
in clinic.
A window trial with 5AZA might be interesting to show the effect of this drug as
single agent.
Introducing the drug into a therapeutic trial in patients with newly diagnosed
myeloblastic leukemia taises two major concerns: a possible decrease in
currently achieved results and unknown long term side effect. We now cure
50% of AML in children and more than 30% in adults. A change of protocol
could worsen those results. Given the data already obtained on the drug,
including better cytotoxic activity than ARA-C with, in addition another
mechanism of action, namely demethylation, a pilot randomized study could be
considered in newly diagnosed patients after a pilot study in patients with
recurrent myeloid leukemia demonstrated safety and preliminary evidence of
efficacy of the proposed regimen.
No study has investigated the long term side effects of 5AZA. Methylation plays
an important role in embyogenesis and fetal development. The effect on the
hemoglobin genes is very well known. Some concerns are therefore evident.
One of the most feared long-term side effects of chemotherapy is secondary
malignancies. Even if the dominant epigenetic effect of 5AZA appears to be
demethylation of TSG88, 5AZA could possibly activate silenced oncogenes. t
has already been shown for the HOX1 gene89. In AML reactivation or
upregulation of oncogenes could potentiate the effects of the epidophylotoxins
and alkylating agents. Clinical studies have to include monitoring for this.
Dose ot5AZA
We observed an effect on te-expression of p15 gene from a concentration of
5AZA of 5 ng/ml but we needed 100 ng/ml for p73 and E-Cadherin. For clinical
studies, depending on the endpoint defined, we could start with a low or a
higher dose of 5AZA. It is flot known which gene needs to be demethylate to
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have an effect, nor the minimal demethylation needed for the effect. A low dose
giving levels around 10 ng/ml could be clinically sufficient. Nevertheless when
we look at our data, the concentrations of 100 ng/ml gave for ail 3 genes an
evident re-expression, which paraileis growth inhibition, inhibition of the DNA
synthesis, and loss of clonogenicity. So we could foresee that a dose, which
would give levels round 100 ng/mi, wouid have more ciinical effects.
Furthermore, the ceils were only treated once for KG1a and once daily for HL
60. So we have an argument to test in ciinicai trials high dose boluses of 5AZA.
Nevertheless the doubling time of the H L-60 and KG1 a may be less than certain
human leukemic clones and the drug in vitro is flot destroyed by deamination
and has a longer half live. Finally increasing the dose in clinical trials might
induce the re-expression of certain genes, which couid carry unwanted effects.
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Ethical Considerations
In this study, we were working on a celi model from an anonymized patient so
very few ethical problems were raised. Anonymization of the celis had already
been performed.
Exarnining the history of 5AZA there are 2 major ethicai points worth noting:
The f irst one concerns the publication of negative results44 fundamental when
we investigate new drugs. The international tendency of flot publishing negative
resuits might give clinicians an erroneous view of the drug. The second one
concerns phase I trials in chiidren. For 5AZA, the first phase I trial was
published in pediatrics39.
Using chiidren as research subjects, is a very controversial issue9° mainly when
t cornes to phase I trials. Research is essential for irnproving cure rates and
quality of lif e. It is not ethical that any social group should be deprived of its
benefits and so, the Arnerican Academy of Pediatrics recommends that children
should benefit f rom research including from phase I trials. Data obtained f rom
adult research is not always vaiid in pediatrics.
Children are a very vulnerable population and should be protected from
research abuse. The Nuremberg code, the Helsinki convention and the
constitution of rnany countries state that no harm is acceptable to children
simply to benefit others. Medications evaluated in phase I studies have a srnall
but real possible therapeutic benefit to offer children with advanced malignant
disease. The overall response rates in phase I studies, depending on the
disease, range f rom <3% to 17.7%, with a toxic rnortality rate of less than 1 %91•
Response may carry clinical benefit, but not in ail cases. The overall impact on
quality of life is uncertain. Eligibility criteria do require that the child be
sufficiently fit physiologically to receive therapy.
Autonomy s also a problem; parents decide on the child’s behalf, particularly in
cases in which the child is less than 10 years of age. In this setting, parents
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may also have unrealistic hopes. Many patients and families seek enrolment on
a phase I study with the expectation of potential improvement92. Physicians
may also expect an overail benefit to the child from enrolment on a phase I
study93’94. An inquiry from the Children’s Oncology Group and the United
Kingdom Children’s Cancer Study Group showed that the majority considered
that there was benefit to the child from participation in a phase I study95. Those
benetits may include psychological benefit, hope and altruism. A phase I study
should intertere as littie as possible with the child’s quality of life. Also, the
patient, if old enough, and family must understand the limited possibility of
ben et it.
In phase II and III trials this controversy is Iess intense due to the possible
benefits that might be anticipated. Currently, given the large number of drugs
being tested an important issue is the choice of which to introduce in the clinic.
Concerning 5AZA, it has shown promising activity and so further studies seem
indicated.
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Final Considerations
In conclusion, there are flot enough data to incorporate 5AZA into a rationally
designed combination regimen. If we accept the hypothesis that gene re
expression is important to the cure of leukemia and if we want to test that re
expression as a surrogate marker, our data present an argument to plan such a
study starting with doses that give levels around 10 ng/mI eventually in
association with histone deacetylase inhibitors.
Further studies in animal models looking for the effect of a intermediate/high
dose scheme (plasma levels 100-200 ng/ml) and testing for different times of
perfusion would be helpful. This could be performed in association with other
drugs used in leukemia and eventually with G-OSE. Similar data should be
obtained with low doses (plasma levels 10-50 ng/mI). It would be interesting to
know which plasma levels we achieve with the small doses used by Issa41 and
correlate them with gene activation, clonogenicity and clinical effects.
In patients with AML, lower doses of 5AZA could be tested in groups flot
expected to tolerate high doses. For the other patients a pilot trial could be used
to test the intermediate/high doses of 5AZA. If initial studies prove promising,
subsequent studies will need to examine late effects as well.
6$
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